Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
Speaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
Similar Posts
Webinar – How to Treat Locoregional Reccurent Disease of Nasopharyngeal Cancer
ByInnokeys
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeys
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…
New Marketing Authorization Approval in The Philippines for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeys
On 18 Sep 2020, Philippines FDA approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for nimotuzumab. This…
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeys
Kowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
ByInnokeys
New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…